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Abstract: A total of 14 novel arylpiperazines were synthesized, and pharmacologic-
ally evaluated by measuring their affinities towards the D2 dopamine receptor 
(D2DR) in a [3H]spiperone competition assay. All herein described compounds 
consist of a benzimidazole moiety connected to the N-(2-methoxyphenyl)pipe-
razine via linkers of various lengths. Molecular docking analysis and molecular 
dynamics simulations were performed on D2DR-arylpiperazine complexes with an 
objective to explore the receptor-ligand interactions and properties of the receptor 
binding site. Crystal structure of D2DR that has been published recently was used 
throughout this study.  
The major finding is that high affinity arylpiperazines must interact with both the 
orthosteric binding site and the extended binding pocket of D2DR and therefore 
should contain a linker of 5 or 6 methylene groups long. 
Keywords: arylpiperazines; molecular dynamics; molecular docking; receptor 
bind site 
INTRODUCTION 
Dopamine receptors belong to rhodopsin-like, aminergic G protein-coupled 
receptors (GPCRs) group. They are involved in many physiological processes 
and play important role in the central nervous system (CNS).1-4  
Targeting the dopamine D2 receptors (D2DR) is a common strategy for the 
treatment of neurodegenerative diseases, like schizophrenia, Parkinson's disease, 
dementia and depression.5-8 
It is a well-documented fact that N-substituted arylpiperazines are 
compounds with pronounced D2DR activity.9,10 Since arylpiperazines have wide 
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spectrum of therapeutic potential and design, synthesis and characterization of 
new arylpiperazine like drugs is ever growing area of research.11-14  
In this paper we present the synthesis of 14 new N-(2-methoxy-
phenyl)piperazines of the general structure 5 (Scheme 1). Their affinities towards 
D2DR were evaluated in [3H]spiperone competition assay. 
Recent discovery of D2DR crystal structure with bound risperidone15 defined 
receptor bind site with greater accuracy then existing homology models. This 
finding, prompted us to investigate D2DR - arylpiperazine binding features, 
using molecular docking analysis and molecular dynamics simulations in order to 
define key receptor-ligand interactions and explain the dopaminergic properties 
of the herein described compounds. 
EXPERIMENTAL 
Reagents and solvents used in this work were obtained from Alfa–Aesar or Sigma 
Aldrich and used without further purification. Solvents were routinely dried over anhydrous 
Na2SO4 prior to evaporation. 
General 
A Boetius PHMK apparatus (VEB Analytic, Dresden, Germany) was used to determine 
melting points, which are presented here uncorrected. The 1H-NMR and 13C-NMR spectra 
were recorded at 200 and 50 MHz, respectively, on a Gemini 2000 (Varian, Oxford). Spectra 
were recorded in deuterochloroform with tetramethylsilane as the internal standard; the 
chemical shifts (δ) are reported in parts per million (ppm); all coupling constants (J values) are 
reported in hertz (Hz). LC/MS was performed on a 6210 Time-of-Flight LC-MS system 
(Agilent Technologies, Germany). For data analysis, MassHunter Workstation Software was 
used. The infrared (IR) spectra were obtained on a Thermo Scientific spectrometer. For 
analytical thin-layer chromatography (TLC), POLYGRAM SIL G/UV254 plastic-backed thin 
layer silica gel plates were used (Macherey-Nagel, Germany). Chromatographic purifications 
were performed on Merck-60 silica gel columns (230–400 mesh ASTM) under medium 
pressure (dry column flash chromatography). A MicroSYNTH Milestone and a Biotage 
Initiator 2.5 EXP were used for the microwave experiments. 
Chemistry 
General procedure for the synthesis of compounds 3a-g: 
Suspension of 1-(2-methoxyphenyl)piperazine (1) (0.084 mol), triethylamine (0.0874 
mol), K2CO3 (0.175 mol) and bromo-ester 2a-g (0.084 mol) in 2-butanone (100 mL) was 
stirred for 24 h at 80°C. After cooling, the mixture was poured into cold water and the organic 
layer was extracted with CH2Cl2 and concentrated in vacuo. The resulting ester was purified 
by silica gel column chromatography using a gradient of methanol (0–5 %) in 
dichloromethane. 
General procedure for the synthesis of compounds 5a-5n:  
Compound 3a-g (0.0035 mol) and diamine 4a-c (0.0035 mol) were suspended in 8 mL 
50 % methanesulfonic acid in water, transferred into a sealed tube, and microwave irradiated 
at 180 °C for 45 min at 300 W. After cooling to room temperature, the reaction mixture was 
poured into ice-cold water and neutralized with a saturated solution of NaOH. The product 
was extracted with CH2Cl2 and concentrated in vacuo. The resulting 1H-benzimidazoles were 
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purified by silica gel column chromatography using a gradient of methanol (0–5 %) in 
dichloromethane.  
Biological assays 
Membrane preparation 
Rat caudate nuclei synaptosomal membranes for D2DR binding experiments were 
prepared as previously described.16 Striatal tissue acquired from male Wistar rats (150–200 g) 
was used as a source of D2DR. Tissue was homogenized in 20 volumes of ice-cold 50 mM 
Tris-HCl buffer containing 120 mM NaCl, 5 mM KCl, 1 mM MgCl2, and 2 mM CaCl2 using 
Potter–Elvehjem homogenizer (6 × 800 rpm). Membrane fraction obtained after centrifugation 
at 20000 rpm for 15 min was used in binding experiments.  
[3H]Spiperone receptor binding assay 
[3H]Spiperone (73.36 Ci /mmol, Perkin Elmer LAS GmbH,Rodgau, Germany) binding 
was assayed in 1.0 mM EDTA, 4 mM MgCl2, 1.5 mM CaCl2, 5 mM KCl, 120 mM NaCl, 25 
mM Tris-HCl solution, pH 7.4, with rat caudate nuclei synaptosomal membranes (protein 
concentration 0.6 mg/mL), at 37 °C for 10 min in a total volume of incubation mixture of 
0.4 mL. Binding of the radioligand to 5-HT2 receptors was prevented by 50 mM ketanserin. 
The Ki values of the tested compounds were determined by competition binding at 0.2 nM of 
the radioligand and eight different concentrations of each compound (10-4 - 10-10 M). 
Nonspeciﬁc binding was determined in the presence of 10 µM spiperone. The reaction was 
terminated by rapid ﬁltration through Whatman GF/C ﬁlters washed three times with 5.0 mL 
of ice-cold incubation buffer, and retained radioactivity was measured in a 1219 Rackbeta 
Wallac scintillation counter (EG&G Wallac, Turku, Finland). Inhibition curve construction 
and statistical (Student’s T-test) analysis were performed by Graph-Pad Prism (GraphPad 
Software Inc). Hill slope coefficients were fixed to unity during calculation.  
Computational study 
Docking simulations 
Docking procedure was carried out using Forecaster software.17 Receptor model PDB 
code 6CM418 was used together with 2D structures of ligands, prepared in ChemDraw.19 All 
structures were prepared in software, using default procedures. Rigid receptor, flexible ligand 
docking was carried out. Obtained docking structures were examined and structures with 
maximum number of receptor – ligand interactions were selected for further analysis. 
Binding poses metadynamics 
Docking pose quality was assessed in terms of the fluctuations of the ligand RMSD (the 
root-mean-square deviation of atomic positions), and the persistence of important contacts 
between the ligand and the receptor (Metadynamics Binding PoseScore and Metadynamics 
Binding Persistence) using Desmond software and default parameters.20 One docking pose 
with the lowest RMSD and best overall score was selected for MD simulations. 
Construction of protein-membrane system for molecular dynamics 
Protein protonation state was adjusted using Schrodinger Protein Preparation module, at 
physiological pH (pH=7.4). Prepared protein was embedded into POPC membrane bilayer 
using Desmond system builder module,20 and oriented according to data from Orientations of 
Proteins in Membranes (OPM) server.21 The embedded protein was solvated with TIP3P 
explicit water model, and system was neutralized via counter ions and salt solution of 0.15 M 
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KCl. In this way, we obtained the systems that were subjected to membrane relaxation 
protocol.20 
MD simulations 
Molecular dynamics (MD) simulations of the system were performed using Schrodinger 
Desmond software packages.20 OPLS 2003 forcefield22 was used to calculate the interactions 
between all the atoms. For the calculation of the long-range Coulombic interactions, particle-
mesh Ewald (PME) method was used, with the cut-off radius of 9 Å for the short-range Van 
der Waals (VdW) and electrostatic interactions.  
During the course of the simulation, constant temperature of 310 K and a pressure of 
1.01235 bars were maintained, using the Nose–Hoover thermostat,23 and the 
Martyna-Tobias-Klein method.24 In the simulations 2.0 fs time increments were used. Finally, 
100 ns MD simulation for the each ligand-D2DR complex was performed and the collected 
trajectory frames used in the MD analysis to quantify the protein-ligand interactions. 
RESULTS AND DISCUSSION 
Compounds 5a-5n were synthesized according to the Scheme 1. The 
synthesis started with N-(2-methoxyphenyl)piperazine (1) that was alkylated with 
a series of homologous bromo-esters 2a-2g, providing N-alkylated products 3a-
3g. Counterpart diamines 4a-4c were obtained by reduction of the corresponding 
2-nitro precursors, using Raney-Ni and hydrazine hydrate under condition 
described in our earlier publications.25,26 Microwave assisted condensation of 
piperazines 3a-3g and diamines 4a-4c, under forcing, strongly acidic conditions, 
secured the desired benzimidazoles 5a-5n. 
 
Scheme 1. Synthesis of the compounds 5a–5n 
n= 1-7 for the compounds 2a-2g, 3a-3g and 5a-5g; ethyl esters of the general structure 2 were 
also used in synthesis 3b, 3c, 3e and 3f; 4a (R= H); 4b (R= OMe); 4c (R= Cl);  
structures 5a-5n are presented in Table1. 
D2DR binding affinities of compounds 5a-5n were evaluated in vitro using 
[3H]spiperone as a standard dopaminergic radioactive ligand (Table I).27 
Molecular docking simulation of herein described {[4-(2-methoxy-
phenyl)piperazin-1-yl]alkyl}-1H-benzo[d]imidazoles on D2DR was performed 
on the D2DR crystal structure published recently by Wang et al.15 They reported 
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that the benzisoxazole moiety of risperidone interact with D2DR through 
Cys1183.36, Thr1193.37, Ser1975.46, Phe1985.47, Phe3826.44, Phe3906.52 and 
Trp3866.48 in the orthosteric binding site (OBS). OBS of D2DR is defined by the 
amino acid side chains of helices III, V and VI and also harbor Asp1143.32. 
Asp1143.32 forms an essential salt-bridge with protonated piperidine nitrogen of 
risperidone molecule. In addition D2DR has a secondary binding pocket, 
extended binding pocket (EBP) that enclose risperidone’s tetrahydropyrido-
pyrimidinone moiety. EBP is bordered by the extracellular part of TM VII con-
sisting of an extracellular loop 1 (EL1) and the junction of helices I, II and VII.15 
TАBLE I. Chemical structures and D2DR binding constants of {[4-(2-methoxyphenyl)pipe-
razin-1-yl]alkyl}-1H-benzo[d]imidazoles (5a-5n) 
 
 
Ligand n R Ki ± S.E.M.[nM] 
5a 1 H >1000 
5b 2 H >1000 
5c 3 H >1000 
5d 4 H >1000 
5e 5 H 24±1 
5f 6 H 16±2 
5g 7 H >1000 
5h 4 OCH3 124±5 
5i 5 OCH3 12±3 
5j 6 OCH3 76±8 
5k 7 OCH3 >1000 
5l 4 Cl 109±9 
5m 5 Cl 25±3 
5n 6 Cl 102±3 
D2DR binding constants (Ki) was determined in a [3H]spiperone displacement assay. The 
values are the mean of three independent experiments done in triplicate performed at eight 
competing ligand concentrations.  
 
Molecular docking simulations on the binding of {[4-(2-
methoxyphenyl)piperazin-1-yl]alkyl}-1H-benzo[d]imidazoles into the crystal 
structure of D2DR show that (2-methoxyphenyl)piperazin moiety occupies 
D2DR OBS, and interacts with Asp1143.32, Cys1183.36, Trp3866.48 and Phe3906.52, 
while the benzimidazole part interacts with Leu942.64, Ile 184EL2,Trp100EL1, 
Phe3896.51, Thr4127.39 and Tyr4087.35 in the EBP (Figure 1.).  
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Figure 1. Docking of ligand 5i to D2DR is presented. View of the interaction between  
3D model of the D2DR binding site and ligand 5i.  
Images are showing only key amino acid residues of the receptor binding pocket. Figures (side 
view-left and top-view right) shows docking of 5i viewed from different angles. Bind site ligand 
accessible surface is shown in the top view. 
Compounds with optimal linker length (five or six methylene groups in 
linker) allow benzimidazole moiety to reach EBP and to interact with Leu942.64, 
Trp100EL1, Phe3896.51, Thr4127.39 and Tyr4087.35 (Figure 2). Compounds with 
shorter linker (5a-5d) do not reach into the EBP, while ligands with seven 
methylene groups in linker (5g, 5k) are too long to fit optimally into the D2DR 
binding cleft and protrude into extracellular space.  
Those results are in agreement with experimental data: compound 5d (with 4 
methylene groups linker) has affinity of over 1000 nM, while compounds 5e and 
5f (with 5 and 6 methylene groups linker) have 24 nM and 16 nM, respectively. 
Compound 5g shows sharp drop in affinity because the length of the linker, that 
cannot be accommodate in D2DR bind cleft.  
In series of compounds substituted with methoxy and chloro groups, highest 
D2DR affinity was obtained with compounds 5i and 5m. Linker with 5 
methylene groups facilitates optimal positioning of substituted benzimidazole 
part in the receptor EBP (Figure 1). Shorter linkers, as it is obvious in series 5h-
5k and 5l-5n, lead to decrease in receptor affinity due to suboptimal placement of 
benzimidazole part in regard to interacting residues Trp100EL1 and Tyr4087.35.  
To test the stability of obtained docking poses, MD simulations of the D2DR 
and selected ligands were performed on inactive receptor state for 100ns for each 
ligand. Obtained trajectories were analyzed with a focus on residues that form 
OBS and EBP (Table 1. in Supplement). 
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Figure 2. – Results of docking simulations for ligand 5e (A) , 5f (B), 5i (C) and  
5m (D) are presented. 
Schematic representation of the best docking pose for all ligands are provided. Only amino acid 
residues in close contact with ligands are shown for clarity. Solid lines represent aromatic, while 
dotted lines represent electrostatic interactions 
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Most of the receptor-ligand interactions in OBS, observed in molecular 
docking simulations persisted for a significant portion of MD run (>20% total 
simulation time). Compounds with significant D2DR affinity (5e-5f, 5h-5j and 
5l-5n) had a salt bridge between the protonated piperazine nitrogen of the ligand 
and Asp1143.32 of D2DR preserved for more than 79%-84% of the simulation 
time. Additional interactions in OBS are aromatic interaction with Cys1183.36 (32-
75% of simulation time), and edge-to-face interactions with Trp3866.48 (76-98% 
of simulation time) and Phe3906.52 (20-49% of simulation time). In the EBP, 
significant interactions are aromatic interactions (edge-to-face type) with 
Trp100EL1, Phe3896.51 and Tyr4087.35. Compounds 5e, 5f, 5i and 5m, form 
additional hydrogen bond with Thr4127.39.  
CONCLUSION 
Molecular docking and MD simulation provide important information that 
explains how the receptor-ligand complexes are formed. High affinity {[4-(2-
Methoxyphenyl)piperazin-1-yl]alkyl}-1H-benzo[d]imidazoles must 
simultaneously occupy both OBS and EBP.  
To establish key interactions both in OBS (salt bridge formation and 
aromatic interactions) and EBP (aromatic interactions and hydrogen bond 
formation), ligands should have a linker of five or six methylene groups. Linker 
flexibility and substituent size in the benzimidazole moiety determine ligand 
positioning inside the EBP and brings it in close contact with Trp100EL1 and 
Tyr4087.35, that are key interacting residues. Also, as can be concluded from the 
results of molecular dynamics, affinity of the arylpiperazine ligands benefit 
greatly from possible formation of the interactions of arylpiperazine part of 
ligands with Thr4127.39 in EBP.  
It is clear that both Trp100EL1 and Tyr4087.35 can form aromatic interactions 
and/or hydrogen bonds. To establish exact nature of interactions in EBP, 
modification of presented ligands, in terms of target synthesis of the compounds 
which can strictly form only one of these interactions, represent a guideline for 
further investigation. 
SUPPLEMENTARY MATERIAL 
Supplementary Material are available electronically from 
http://www.shd.org.rs/JSCS/, or from the corresponding author on request. 
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И З В О Д  
СИНТЕЗА НОВИХ ДЕРИВАТА ПИПЕРАЗИНО-АЛКИЛ-1Н-БЕНЗО[d]ИМИДАЗОЛА И 
ПРОУЧАВАЊЕ ИНТЕРАКЦИЈА СА Д2 ДОПАМИНСКИМ РЕЦЕПТОРОМ 
ЈЕЛЕНА З. ПЕЊИШЕВИЋ1, ДЕАНА Б. АНДРИЋ2, ВЛАДИМИР Б. ШУКАЛОВИЋ1, ГОРАН М. РОГЛИЋ2, 
 ВУКИЋ ШОШКИЋ3, СЛАЂАНА В. КОСТИЋ-РАЈАЧИЋ1 
1ИХТМ-Центар за хемију, Универзитет у Београду, Његошева 12, 11000 Београд, Србија; 2Хемијски 
факултет, Универзитет у Београду, Студентски трг12-16, 11000 Београд, Србија ; 3Orgentec GmbH, 
Carl-Zeiss-Str. 49, 55129 Mainz, Germany 
У овом раду је презентована синтеза 14 нових арилпиперазина и одређен је њихов 
афинитет везивања за Д2 допамински рецептор (Д2ДР) тестовима компетиције са 
[3H]спипероном. По својој хемијској структури ова једињења представљају супституисане 
бензимидазоле повезане са N-(2-метоксифенил)пиперазинским делом, линкерима 
различитих дужина. У циљу испитивања лиганд-рецептор интеракција и особина везивног 
места Д2ДР, урађена је докинг анализа новосинтетисаних једињења и симулација 
молекулске динамике, користећи кристалну структуру рецептора.  
Резултати добијени у овом раду указују да арилпиперазини високог афинитета 
остварују интеракције у ортостерном везивном месту и у екстензији ортостерног места 
везивања Д2ДР и да стога треба да поседују линкер оптималне дужине, од 5 или 6 
метиленских група. 
(Примљено 29. октобра; ревидирано 3. децембра; прихваћено 4. децембра 2018) 
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SUPPLEMENTARY MATERIAL TO 
Synthesis of novel piperazino-alkyl-1H-benzo[d]imidazole 
derivates and assessment of their interactions with the D2 
dopamine receptor 
JELENA Z. PENJIŠEVIĆ1, DEANA B. ANDRIĆ2, VLADIMIR B. ŠUKALOVIĆ1,  
GORAN M. ROGLIĆ2, VUKIĆ ŠOŠKIĆ3 and SLAĐANA V. KOSTIĆ-RAJAČIĆ1,* 
1ICTM-Department of Chemistry, University of Belgrade, Njegoševa 12, 11000 Belgrade, 
Serbia; 2Faculty of Chemistry, University of Belgrade, Studentski trg 12-16, 11000 Belgrade, 
Serbia; 3Orgentec GmbH, Carl-Zeiss-Str. 49, 55129 Mainz, Germany 
ANALYTICAL AND SPECTRAL DATA FOR THE SYNTHESIZED COMPOUNDS 
Methyl 2-[4-(2-methoxyphenyl)piperazin-1-yl]acetate (3a):  
Yield: 95.3 %; orange crystals m.p. 50 °C; IR (ATR, cm-1): 2820.2, 1724.3, 
1500.9, 1451.7, 1241.4, 1027.1, 751.3; 1H-NMR (200 MHz, CDCl3) δ: 2.75-2.80 
(m, 4H, piperazine), 3.12-3.17 (m, 4H, piperazine), 3.29 (s, 2H, CH2), 3.74 (s, 
3H, -COCH3), 3.85 (s, 3H, OCH3), 6.84-7.01 (m, 4H, ArH); 13C-NMR (50 MHz, 
CDCl3) δ: 50.22, 51.56, 53.20, 55.16, 59.43, 111.01, 118.11, 120.86, 122.86, 
141.03, 152.10, 170.64; MS: m/z [M+H]+ calculated for C14H20N2O3 265.15467, 
found 265.15493. 
Ethyl 3-[4-(2-methoxyphenyl)piperazin-1-yl]propanoate (3b):  
Yield: 84.2 %; oil; IR (ATR, cm-1): 2818.6, 1734.0, 1501.0, 1452.7, 1241.3, 
1026.5, 749.6; 1H-NMR (200 MHz, CDCl3) δ: 1.28 (t, 3H, J=7.4 Hz, CH3), 2.51-
2.59 (m, 2H, CH2), 2.66-2.71 (m, 4H, piperazine), 2.75-2.83 (m, 2H, CH2), 3.08-
3.10 (m, 4H, piprazine), 3.86 (s, 3H, OCH3), 4.16 (q, J=7.4 Hz, J=11.4 Hz, 2H, 
COCH2), 6.84-7.03 (m, 4H, ArH); 13C-NMR (50 MHz, CDCl3) δ: 14.04, 32.13, 
50.39, 52.94, 53.45, 55.13, 60.17, 110.99, 118.00, 120.80, 122.73, 141.12, 
152.08, 172.35; MS: m/z [M+H]+ calculated for C16H24N2O3, 293.18597, found 
293.18584.  
Ethyl 4-[4-(2-methoxyphenyl)piperazin-1-yl]butanoate (3c):  
Yield: 86.6 %; oil; IR (ATR, cm-1): 2817.0, 1732.8, 1501.1, 1452.5, 1241.3, 
1028.1, 750.6; 1H-NMR (200 MHz, CDCl3) δ: 1.26 (t, 3H, J= 7.4 Hz, CH3), 1.78-
1.93 (m, 2H, CH2), 2.33-2.47 (m, 4H, CH2), 2.63-2.66 (m, 4H, piperazine), 3.09 
                                                                                                              
*Corresponding author E-mail: srkostic@chem.bg.ac.rs  
https://doi.org/10.2298/JSC181029104P  
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(s, 4H, piperazine), 3.86 (s, 3H, OCH3), 4.13 (q, 2H, J= 6.6 Hz, J= 7.4 Hz, 
COCH2), 6.83-7.04 (m, 4H, ArH); 13C-NMR (50 MHz, CDCl3) δ: 14.11, 22.03, 
32.19, 50.52, 53.23, 55.18, 57.64, 60.12, 111.01, 118.03, 120.84, 122.73, 141.25, 
152.16, 173.49; MS: m/z [M+H]+ calculated for C17H26N2O3 307.20162, found 
307.20152. 
Methyl 5-[4-(2-methoxyphenyl)piperazin-1-yl]pentanoate (3d):  
Yield: 69.0 %; oil; IR (ATR, cm-1): 2818.4, 1737.6, 1500.9, 1450.9, 1241.1, 
1027.2, 751.1; 1H-NMR (200 MHz, CDCl3) δ: 1.67-1.71 (m, 4H, CH2), 2.35-2.38 
(m, 2H, CH2), 2.51-2.54(m, 2H, CH2), 2.76(s, 4H, piperazine), 3.17 (s, 4H, 
piperazine), 3.67 (S, 3H, CH3), 3.86 (m, 3H, OCH3), 6.85-7.02 (m, 4H, ArH); 
13C-NMR (50 MHz, CDCl3) δ: 22.41, 25.80, 33.35, 50.10, 50.90, 52.93, 54.78, 
57.70, 110.64, 117.63, 120.47, 122.33, 140.85, 151.75, 173.40; MS: m/z [M+H]+ 
calculated for C17H26N2O3 307.20162, found 307.20075. 
Ethyl 6-[4-(2-methoxyphenyl)piperazin-1-yl]hexanoate (3e): 
Yield: 91.0%; oil; IR (ATR, cm-1): 2814.2, 1734.5, 1501.2, 1452.5, 1240.9, 
1029.8, 748.0; 1H-NMR (200 MHz, CDCl3) δ: 1.22 ( t, 3H, J=7.4 Hz, CH3 ), 
1.29-1.39 (m, 2H, CH2), 1.45-1.71 (m, 4H, CH2), 2.24-2.41 (m, 4H, CH2), 2.61 
(s, 4H, piperazine), 3.07 (s, 4H, piperazine), 3.82 (s, 3H, OCH3), 4.09 (q, 2H, J=6 
Hz, J= 8 Hz, COCH2), 6.80-7.00 (m, 4H, ArH); 13C-NMR (50 MHz, CDCl3) δ: 
14.07, 24.72, 26.42, 26.96, 34.08, 50.47, 53.33 55.13, 58.42, 60.01, 110.95, 
118.00, 120.80, 122.70, 141.23, 152.10, 173.59; MS: m/z [M+H]+ calculated for 
C19H30N2O3 335.23292, found 335.23342. 
Ethyl 7-[4-(2-methoxyphenyl)piperazin-1-yl]heptanoate (3f):  
Yield: 92.2%; oil; IR (ATR, cm-1): 2818.4, 1734.5, 1501.4, 1450.3, 1240.1, 
1028.6, 750.3; 1H-NMR (200 MHz, CDCl3) δ: 1.20 (t, 3H, J=7.4 Hz, CH3), 1.28-
1.34 (m, 4H, CH2), 1.46-1.63 (m, 4H, CH2), 2.21-2.35 (m, 4H, CH2), 2.60 (s, 4H, 
piperazine), 3.06 (s, 4H, piperazine), 3.80 (s, 3H, OCH3), 4.07 (q, 2H, J=7.2 Hz, 
J=7.4 Hz, COCH2), 6.78-6.99 (m, 4H, ArH); 13C-NMR (50 MHz, CDCl3) δ: 
14.02, 24.65, 26.52, 27.03, 28.82, 34.03, 50.43, 53.29, 55.07, 58.53, 59.90, 
110.90, 117.94, 120.75, 122.62, 141.19, 152.05, 173.55; MS: m/z 
[M+H]+calculated for C20H32N2O3 349.24857, found 349.24825. 
Methyl 8-(4-(2-methoxyphenyl)piperazin-1-yl)octanoate (3g): 
Yield: 82.8 %; oil; IR (ATR, cm-1): 2828.2, 1754.6, 1521.4, 1448.8, 1236.3, 
1025.6, 755.4; 1H NMR (200 MHz, CDCl3) δ: 1.26-1.32 (m, 6H, CH2 ), 1.53-
1.66 (m, 4H, CH2), 2.27-2.43 (m, 4H, CH2), 2.65-2.67 (m, 4H,piperazine), 3.11 
(s, 4H, piperazine), 3.67 (s, OCH3), 3.86 (s, 3H, OCH3), 6.84-7.04 (m, 4H, ArH); 
13C NMR (50 MHz, CDCl3) δ: 24.79, 26.74, 27.34, 29.09, 33.97, 50.56 , 51.33, 
53.43, 55.25, 58.76, 111.06, 118.12, 120.91, 122.79, 141.33, 152.22, 174.24; 
MS: m/z [M+H]+ calculated for C20H32N2O3 349.24857, found 349.24849. 
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2-{[4-(2-methoxyphenyl)piperazin-1-yl]methyl}-1H-benzo[d]imidazole (5a): 
Yield: 16 %; oil; IR (ATR, cm-1): 2817.2, 1502.0, 1455.7, 1240.3, 1026.5, 
743.0; 1H NMR (200 MHz, CDCl3) δ: 2.75-2.80 (m, 4H, piperazine), 3.08-3.13 
(m, 4H, piperazine), 3.84 (s, 3H, OCH3), 3.91 (s, 2H, CH2), 6.84-7.06 (m, 4H, 
ArH), 7.20-7.27 (m, 2H, ArH), 7.57-7.60 (m, 2H, ArH); 13C NMR (50 MHz, 
CDCl3) δ: 50.41 , 53.64, 55.31, 56.46, 111.23, 118.14, 120.93, 122.02, 122.40, 
123.11, 140.90, 151.90, 152.23; MS: m/z [M+H]+ calculated for C19H22N4O 
323.18664, found 323.18515. 
2-{2-[4-(2-methoxyphenyl)piperazin-1-yl]ethyl}-1H-benzo[d]imidazole (5b):  
Yield: 36.5 %; oil; IR (ATR, cm-1): 2818.4, 1500.6, 1456.7, 1240.0, 1026.3, 
745.2; 1H NMR (200 MHz, CDCl3) δ: 2.77-2.92 (m, 6H, 4H piperazine and 
CH2), 3.11-3.18 (m, 6H, 4H piperazine and CH2) 3.87 (s, 3H, OCH3), 6.87-7.04 
(m, 4H, ArH), 7.17-7.25 (m, 2H, ArH), 7.52-7.57 (m, 2H,ArH); 13C NMR (50 
MHz, CDCl3) δ: 25.03, 50.76, 52.94, 55.33, 58.06, 111.23, 114.67, 118.13, 
120.95, 122.02, 123.24, 140.78, 152.21, 154.52; MS: m/z [M+H]+ calculated for 
C20H24N4O 337.20229, found 337.20205. 
2-{3-[4-(2-methoxyphenyl)piperazin-1-yl]propyl}-1H-benzo[d]imidazole (5c):  
Yield: 55.7 %; oil; IR (ATR, cm-1): 2825.5, 1500.7, 1452.9, 1241.4, 1026.5, 
746.5; 1H NMR (200, MHz, CDCl3) δ: 1.96-2.08 (m, 2H, CH2), 2.64 (t, 2H, J=5.6 
Hz, CH2), 2.72 (s, 4H, piperazine), 3.06-3.16 (m, 6H, 4H piperazine and CH2), 
3.85 (s, 3H, OCH3), 6.86-7.05 (m, 4H, ArH), 7.16-7.18 (m, 2H, ArH), 7.52-7.57 
(m, 2H, ArH); 13C NMR (50 MHz, CDCl3) δ: 23.61, 28.90, 50.49, 53.25, 55.24, 
58.72, 111.18, 114.46, 118.03, 120.98, 121.66, 123.18, 140.77, 152.18, 155.58; 
MS: m/z [M+H]+ calculated for C21H26N4O 351.21794, found 351.21682. 
2-{4-[4-(2-methoxyphenyl)piperazin-1-yl]butyl}-1H-benzo[d]imidazole (5d):  
Yield: 90.6 %; oil; IR (ATR, cm-1): 2818.3, 1499.7, 1456.0, 1244.1, 1028.9, 
793.3; 1H NMR (200 MHz, CDCl3) δ: 1.55-1.70 (m, 2H,CH2), 1.83-1.94 (m, 
2H,CH2), 2.43 (t, 2H, J=6.8 Hz, CH2), 2.64 (s, 4H, piperazine), 2.98 (t, 2H, J=6.8 
Hz, CH2), 3.12(s, 4H,piperazine), 3.84 (s, 3H, OCH3), 6.84-7.05 (m, 4H, ArH), 
7.14-7.21 (m, 2H,ArH), 7.51-7.56 (m, 2H, ArH); 13C NMR (50 MHz, CDCl3) δ: 
25.38, 25.81, 28.45, 50.34, 53.18, 55.24, 57.24, 111.19, 114.52, 118.16, 120.98, 
121.88, 123.08, 138.57, 140.94, 152.19, 155.38; MS: m/z [M+H]+ calculated for 
C22H28N4O 365.23359, found 365.23263.  
2-{5-[4-(2-methoxyphenyl)piperazin-1-yl]pentyl}-1H-benzo[d]imidazole (5e): 
Yield: 43.0 %; brown crystals m.p. 63°C; IR (ATR, cm-1): 2825.2, 1500.3, 
1454.9, 1240.7, 1023.6, 752.8; 1H NMR (200 MHz, CDCl3) δ: 1.33-1.48 (m, 
2H,CH2), 1.60-1.75 (m, 2H, CH2), 1.80-1.93 (m, 2H, CH2), 2.54-2.62 (m, 2H, 
CH2), 2.84-2.95 (m, 6H, CH2 and 4H piperazine), 3.17-3.19 (m, 4H, piperazine), 
3.86 (s, 3H, OCH3), 6.85-7.06 (m, 4H, ArH), 7.19-7.22 (m, 2H, ArH), 7.54-7.58 
(m, 2H, ArH); 13C NMR (50 MHz, CDCl3) δ: 25.54, 26.62, 27.82, 28.84, 49.94, 
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53.00, 55.20, 57.97, 111.15, 114.50, 118.18, 120.95, 121.88, 123.10, 138.52, 
140.78, 152.12, 155.31; MS: m/z [M+H]+ calculated for C23H30N4O 379.24924, 
found 379.24889. 
2-{6-[4-(2-methoxyphenyl)piperazin-1-yl]hexyl}-1H-benzo[d]imidazole (5f):  
Yield: 69.0 %; brown crystals m.p. 134 °C; IR (ATR, cm-1): 2828.5, 1503.0; 
1454.6, 1240.6, 1019.5, 750; 1H NMR (200 MHz, CDCl3) δ: 1.26-1.58 (m, 6H, 
CH2), 1.76-1.92 (m, 2H, CH2), 2.37 (t, 2H, J=7.4 Hz, CH2), 2.61-2.65 (m, 
4H,piperazine), 2.90 (t, 2H, J=8 Hz, CH2), 3.11 (s, 4H, piperazine), 3.85 (s, 3H, 
OCH3), 6.84-7.04 (m, 4H, ArH), 7.18-7.27 (m, 2H, ArH), 7.51-7.58 (m, 2H, 
ArH); 13C NMR (50 MHz, CDCl3) δ: 26.12, 26.94, 28.00, 28.96, 29.13, 50.29, 
53.20, 55.22, 58.37, 111.13, 114.54, 118.18, 121.97, 121.89, 123.02, 138.55, 
141.01, 152.17, 155.38; MS: m/z [M+H]+ calculated for C24H32N4O 393.26489, 
found 393.26320.  
2-{7-[4-(2-methoxyphenyl)piperazin-1-yl]heptyl}-1H-benzo[d]imidazole (5g):  
Yield: 72.0 %; oil; IR (ATR, cm-1): 2962,9, 1497,9, 1449,6, 1261,7, 1026,4, 
744,5; 1H NMR (200 MHz, CDCl3) δ: 1.26-1.49 (m, 8H, CH2), 1.79-1.86 (m, 2H, 
CH2), 2.38 (t, 2H, J=7.4 Hz, CH2), 2.68 (s, 4H, piperazine), 2.89 (t, 2H, J=8 Hz, 
CH2), 3.13 (s, 4H, piperazine), 3.85 (s, 3H, OCH3), 6.84-6.94 (m, 4H, ArH), 
7.19-7.24 (m, 2H, ArH), 7.52-7.56 (m, 2H, ArH); 13C NMR (50 MHz, CDCl3) δ: 
26.45, 27.21, 28.11, 29.05, 29.29, 50.40, 53.35 , 55.28, 58.65, 111.13, 114.64, 
118.22, 120.98, 121.99, 123.01, 138.47, 141.11, 152.22, 155.26; MS: m/z 
[M+H]+ calculated for C25H34N4O 407.28054, found 407.28007. 
5-methoxy-2-{4-[4-(2-methoxyphenyl)piperazin-1-yl]butyl}-1H-benzo[d]imidazole (5h): 
Yield: 88.0%; oil; IR (ATR, cm-1): 2817.0, 1498.4, 1458.2, 1237.6, 1027, 
751.2; 1H NMR (200 MHz, CDCl3) δ: 1.64-1.76 (m, 2H, CH2), 1.84-1.98 (m, 2H, 
CH2), 2.49 (t, 2H , J=7.4 Hz, CH2), 2.70 (s, 4H, piperazine), 2.96 (t, 2H, J=7.2 
Hz, CH2), 3.16 (s, 4H, piperazine), 3.83 (s, 3H, OCH3,), 3.87 (s, 3H, OCH3), 
6.81-7.08 (m, 7H, ArH); 13C NMR (50 MHz, CDCl3) δ: 25.09, 25.87, 28.40, 
50.54, 53.31, 55.33, 55.82, 57.09, 111.17, 118.18, 121.02, 123.17, 141.03, 
152.26, 155.98; MS: m/z [M+H]+ calculated for C23H30 N4O2 395.24415, found 
395.24331. 
5-methoxy-2-{5-[4-(2-methoxyphenyl)piperazin-1-yl]pentyl}-1H-benzo[d]imidazole (5i): 
 Yield: 73.0%; oil; IR (ATR, cm-1): 2832.2, 1500.2, 1455.8, 1242.6, 1027.7, 
752.9; 1H NMR (200 MHz, CDCl3) δ: 1.38-1.45 (m, 2H, CH2), 1.71-1.90 (m, 4H, 
CH2), 2.77-2.94 (m, 4H, CH2), 3.09 (s ,4H, piperazine), 3.28 (s, 4H,piperazine), 
3.83 (s, 3H, OCH3), 3.87 (s, 3H, OCH3), 6.82-6.92 (m, 4H, ArH), 7.02-7.08 (m, 
2H, ArH), 7.46 (d, 2H, J=8Hz, ArH); 13C NMR (50 MHz, CDCl3) δ: 22.59, 
22.97, 25.21, 27.00, 48.25, 52.18, 55.38, 55.80, 56.82, 97.42, 111.26, 111.63, 
115.19, 118.51, 121.09, 123.92, 138.19, 139.72, 152.10, 154.72, 156.18; MS: 
m/z [M+H]+ calculated for C24H32N4O2 409.25980, found 409.26000. 
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5-methoxy-2-{6-[4-(2-methoxyphenyl)piperazin-1-yl]hexyl}-1H-benzo[d]imidazole (5j): 
Yield: 67.1%; oil; IR (ATR, cm-1): 2856.0, 1501.3, 1457.2, 1247.5, 1026.2, 
753.3; 1H NMR (200 MHz, CDCl3) δ: 1.35-1.55 (m, 4H,CH2), 1.63-1.88 (m, 
2H,CH2), 2.41 (t, 2H, J=8 Hz, CH2), 2.67-2.72 (m ,4H, piperazine), 2.85 (t, 2H, 
J=7.4 Hz, CH2), 3.10-3.15 (m, 4H, piperazine), 3.79 (s, 3H, OCH3), 3.85 (s, 3H, 
OCH3), 4.21-4.24 (m, 2H, CH2), 6.81-7.03 (m, 4H, ArH), 7.38-7.43 (m, 1H, 
ArH), 7.50-7.55 (m, 1H, ArH), 7.67-7.74 (m, 1H, ArH); 13C NMR (50 MHz, 
CDCl3) δ: 22.85, 23.59, 25.83, 26.78, 27.82, 50.05, 53.11, 55.24, 55.71, 58.22, 
97.59, 111.12, 115.16, 118.18, 120.95, 123.10, 130.85, 140.87, 152.14, 154.98, 
155.91; MS: m/z [M+H]+ calculated for C25H34N4O2 423.27545, found 
423.27570. 
5-methoxy-2-(7-(4-(2-methoxyphenyl)piperazin-1-yl)heptyl)-1H-benzo[d]imidazole (5k): 
Yield: 62.3%; oil; IR (ATR, cm-1): 2927.7, 1501.3, 1499.0, 1453.5, 1240.3, 
1026.6, 748.2; 1H NMR (200 MHz, CDCl3) δ: 1.58 (s, 6H, CH2), 2.16-2.23 (m, 
2H, CH2), 2.53 (s, 2H, CH2), 2.85 (s, 6H, 4H piperazine and CH2), 3.15 (s, 6H, 
4H piperazine and CH2), 3.81 (s, 3H, OCH3), 3.85 (s, 3H, OCH3), 6.84-7.01 (m 
7H, ArH); 13C NMR (50 MHz, CDCl3) δ: 25.57, 27.13, 29.13, 49.53, 52.60, 
55.31, 55.77, 57.9 , 97.67, 111.11, 118.29, 120.99, 123.20, 140.74, 152.14, 
154.93, 155.96; MS: m/z [M+H]+ calculated for C26H36N4O2 437.29110, found 
437.29115. 
5-chloro-2-{4-[4-(2-methoxyphenyl)piperazin-1-yl]butyl}-1H-benzo[d]imidazole (5l):  
Yield: 88,4%; oil; IR (ATR, cm-1): 2811.0, 1501.1, 1447.5, 1239.6, 1027.4, 
751.2; 1H NMR (200 MHz, CDCl3) δ: 1.59-1.69 (m, 2H, CH2), 1.82-1.96 (m, 
2H,CH2), 2.39 (t, 2H, J=7.2 Hz, CH2), 2.65 (s, 4H, piperazine), 2.96 (t, 2H, J=6.6 
Hz, CH2), 3.12 (s, 4H, piperazine), 3.84 (s, 3H, OCH3), 6.84-7.02 (m, 4H, ArH), 
7.12-7.17 (m, 1H, ArH), 7.39-7.50 (m, 2H, ArH); 13C-NMR (50 MHz, CDCl3) δ: 
25.18, 25.83, 28.45, 50.38, 53.18, 55.24, 57.11, 111.12, 114.48, 115.19, 118.16, 
120.97, 122.39, 123.17, 127.43, 140.79, 152.16, 156.67; MS: m/z [M+H]+ 
calculated for C22H27ClN4O 399.19462, found 399.19367.  
5-chloro-2-{5-[4-(2-methoxyphenyl)piperazin-1-yl]pentyl}-1H-benzo[d]imidazole (5m):  
Yield: 65%; oil; IR (ATR, cm-1): 2824.8, 1500.7, 1450.7, 1241.2, 1027.0, 
749.9; 1H NMR (200 MHz, CDCl3) δ: 1.35-1.62 (m, 4H, CH2), 1.77-1.91 (m, 
2H, CH2), 2.39 (t, 2H, J=8 Hz, CH2), 2.64 (s, 4H, piperazine), 2.89 (t, 2H, J=8 
Hz, CH2), 3.11 (s, 4H, piperazine), 3.85 (s, 3H, OCH3), 6.84-7.06 (m, 4H, ArH), 
7.13-7.18 (m, 1H, ArH), 7.40-7.50 (m, 2H, ArH); 13C NMR (50 MHz, CDCl3) δ: 
25.96, 26.63, 27.67, 28.98, 50.38, 53.33, 55.27, 58.22, 111.15, 118.20, 121.00, 
122.50, 123.13, 127.58, 140.96, 152.19, 156.32; MS: m/z [M+H]+ calculated for 
C23H29ClN4O 413.21027, found 413.20891. 
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5-chloro-2-{6-[4-(2-methoxyphenyl)piperazin-1-yl]hexyl}-1H-benzo[d]imidazole (5n):  
Yield: 74%; oil; IR (ATR, cm-1): 2825.8, 1500.6, 1451.2, 1241.8, 1027.6, 
750.4; 1H NMR (200 MHz, CDCl3) δ: 1.30-1.46 (m, 6H, CH2), 1.72-1.83 (m, 2H, 
CH2), 2.34 (t, 2H, J=8.6 Hz, CH2), 2.63 (s, 4H, piperazine), 2.86 (t, 2H, J=7.4 Hz, 
CH2), 3.09 (s, 4H, piperazine), 3.84 (s, 3H, OCH3), 6.84-7.06 (m, 4H, ArH), 
7.12-7.18 (m, 1H, ArH), 7.38-7.48 (m, 2H, ArH); 13C NMR (50 MHz, CDCl3) δ: 
26.27, 26.96, 27.91, 28.89, 29.09, 50.45, 53.27, 55.22, 58.42, 111.10, 118.16, 
120.97, 122.46, 123.08, 127.52, 140.98, 152.14, 156.51; MS: m/z [M+H]+ 
calculated for C24H31ClN4O 427.22592, found 427.22408. 
SUMMARY RESULTS OF MD SIMULATIONS 
Table S1. D2DR-ligand key interactions observed in 100 ns MD simulatios.  
Residue 
L
eu
 9
4
 
T
rp
 1
0
0
 
A
sp
 1
1
4
 
C
y
s 
1
1
8
 
Il
e 
1
8
4
 
P
h
e 
3
8
2
 
T
rp
 3
8
6
 
P
h
e 
3
8
9
 
P
h
e 
3
9
0
 
T
y
r 
4
0
8
 
T
h
r 
4
1
2
 
T
y
r 
4
1
6
 
Ligand 
5e  54 81 68 27  76 65 42 65 37  
5f 21 31 79 36 40  82 74 20 33 42  
5h  67 81 58   84 85 24 36   
5i 50 89 80 75   96 84 42 22 30  
5j 36 94 82 73 24 32 98 53 31 25   
5l  22 82 64 26  95 75 34 37   
5m  75 84 69   78 50 49 63 40  
5n 32 42 80 32   82 68 35 28  32 
 
D2DR-ligand interactions presented in more than 20% of MS simulation 
time are shown. Numbers provided in the table refers to the percentage of the 
total simulation time one interaction observed to occur. Interacting residues in 
OBS are shaded in grey colour; residues found in EBP are white. 
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